Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases

Inflammatory diseases including COVID-19 are associated with a cytokine storm characterized by high interleukin-6 (IL-6) titers. In particular, while recent studies examined COVID-19 associated arrhythmic risks from cardiac injury and/or from pharmacotherapy such as the combination of azithromycin (AZM) and hydroxychloroquine (HCQ), the role of IL-6 per se in increasing the arrhythmic risk remains poorly understood. The objective is to elucidate the electrophysiological basis of inflammation-associated arrhythmic risk in the presence of AZM and HCQ. IL-6, AZM and HCQ were concomitantly administered to guinea pigs in-vivo and in-vitro. Electrocardiograms, action potentials and ion-currents were analyzed. IL-6 alone or the combination AZM + HCQ induced mild to moderate reduction in heart rate, PR-interval and corrected QT (QTc) in-vivo and in-vitro. Notably, IL-6 alone was more potent than the combination of the two drugs in reducing heart rate, increasing PR-interval and QTc. In addition, the in-vivo or in-vitro combination of IL-6 + AZM + HCQ caused severe bradycardia, conduction abnormalities, QTc prolongation and asystole. These electrocardiographic abnormalities were attenuated in-vivo by tocilizumab (TCZ), a monoclonal antibody against IL-6 receptor, and are due in part to the prolongation of action potential duration and selective inhibition of Na+, Ca2+ and K+ currents. Inflammation confers greater risk for arrhythmia than the drug combination therapy. As such, in the setting of elevated IL-6 during inflammation caution must be taken when co-administering drugs known to predispose to fatal arrhythmias and TCZ could be an important player as a novel anti-arrhythmic agent. Thus, identifying inflammation as a critical culprit is essential for proper management.

Automated summary

Inflammatory diseases like COVID-19 are associated with a cytokine storm characterized by high levels of interleukin-6 (IL-6). This study aims to understand the electrophysiological basis of inflammation-associated arrhythmic risk with the presence of azithromycin (AZM) and hydroxychloroquine (HCQ). The results show that IL-6 alone or in combination with AZM and HCQ can cause mild to moderate reductions in heart rate, PR-interval, and corrected QT (QTc). IL-6 alone is more potent in affecting these measurements compared to the combination of drugs. Additionally, the combination of IL-6, AZM, and HCQ can lead to severe bradycardia, conduction abnormalities, and QTc prolongation. These abnormalities can be attenuated by tocilizumab (TCZ), a monoclonal antibody against IL-6 receptor, and are attributed to changes in action potentials and ion-currents. Inflammation poses a greater risk for arrhythmia than the drug combination therapy.